En studie for å undersøke Ronde-Cel versus Investigator's Choice CD19 CAR T-cellebehandling (PiNACLE-H2H)
En fase 3-randomisert kontrollert studie av Rondecabtagene Autoleucel, en autolog, dual-målrettet CD19/CD20 CAR T-celleproduktkandidat, kontra etterforskers valg av CD19 CAR T-cellebehandling hos pasienter med tilbakefall eller ildfast stor B-celle-lymfom i den andre linjen med pasienter med tilbakefall eller ildfast
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Studieoversikt
Status
Status
Forhold
Forhold
- Lymfom, B-celle
- Diffust storcellet B-celle lymfom refraktær
- Non-Hodgkin lymfom
- Refraktært non-Hodgkin lymfom
- Stort B-celle lymfom
- Diffust storcellet B-celle lymfom har fått tilbakefall
- Residiverende non-Hodgkin lymfom
- Diffust storcellet B-celle lymfom (DLBCL)
- Non-Hodgkin lymfom refraktært/ tilbakefall
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Mary Lessig, MS
- Telefonnummer: 000-000-0000
- E-post: clinicaltrials@lyell.com
Studer Kontakt Backup
- Navn: James Dean, MD, PhD
- Telefonnummer: 000-000-0000
- E-post: clinicaltrials@lyell.com
Studiesteder
-
-
Queensland
-
Douglas, Queensland, Australia, 4814
- Rekruttering
- Townsville University Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Rekruttering
- The Alfred
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Rekruttering
- Princess Margaret Cancer Centre
-
-
-
-
Arizona
-
Gilbert, Arizona, Forente stater, 85234
- Rekruttering
- Banner MD Anderson Cancer Center
-
Scottsdale, Arizona, Forente stater, 85258
- Rekruttering
- Honor Health
-
Scottsdale, Arizona, Forente stater, 85259
- Rekruttering
- Mayo Clinic Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Har ikke rekruttert ennå
- University of Arkansas
-
-
California
-
Los Angeles, California, Forente stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- University of California, Los Angeles (UCLA)
-
Orange, California, Forente stater, 92868
- Rekruttering
- University of California, Irvine
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- University of Colorado
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- Rekruttering
- MedStar Georgetown University Hospital
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Mayo Clinic Florida
-
Orlando, Florida, Forente stater, 32804
- Rekruttering
- AdventHealth
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
- Rekruttering
- Northside Hospital
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa
-
-
Kansas
-
Westwood, Kansas, Forente stater, 66205
- Rekruttering
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- University of Louisville Health
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Rekruttering
- Tufts Medical Center
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68105
- Rekruttering
- University of Nebraska Medical Center (UNMC)
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- Hackensack
-
Morristown, New Jersey, Forente stater, 07960
- Rekruttering
- Atlantic Health
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87102
- Rekruttering
- University of New Mexico Comprehensive Cancer Center
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Rekruttering
- Roswell Park Comprehensive Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27705
- Rekruttering
- Duke Cancer Institute
-
Winston-Salem, North Carolina, Forente stater, 27157
- Har ikke rekruttert ennå
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- Rekruttering
- University of Cincinnati
-
Cincinnati, Ohio, Forente stater, 45242
- Rekruttering
- Oncology Hematology Care Clinical Trials
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinical Taussig Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Har ikke rekruttert ennå
- Allegheny Health Network
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Forente stater, 78704
- Rekruttering
- St. David's South Austin Medical Center
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- University of Texas Southwestern Medical Center
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Texas Transplant Institute
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84143
- Rekruttering
- Intermountain Healthcare
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- Virginia Commonwealth University-Massey Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Rekruttering
- Medical College of Wisconsin
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
-
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
-
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
-
Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Key Exclusion Criteria:
- Patients ineligible to receive CD19 CAR T-cell therapy
- Primary CNS lymphoma
- Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
- Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
- Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Rondecabtagene Autoleucel
|
An autologous, dual-targeting CD19/20 CAR T-cell candidate.
Andre navn:
|
|
Aktiv komparator: Investigator's Choice CD19
axicabtagene ciloleucel, lisocabtagene maraleucel |
An autologous CD19 CAR T-cell therapy
Andre navn:
An autologous CD19 CAR T-cell therapy
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Event free survival
Tidsramme: 36 months
|
The time interval from treatment initiation until the occurrence of a specific event of interest. |
36 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate
Tidsramme: 36 months
|
Best Overall Response per Lugano Criteria |
36 months
|
|
Complete Response Rate
Tidsramme: 36 months
|
Complete Response per Lugano Criteria |
36 months
|
|
Progression Free Survial
Tidsramme: 36 months
|
The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. |
36 months
|
|
Overall Survival
Tidsramme: 6 years
|
The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive. |
6 years
|
|
Incidence and severity adverse events
Tidsramme: 36 months
|
To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities. |
36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- LYL314-102
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .